CLYM Stock Analysis: Buy, Sell, or Hold?
CLYM - Climb Bio, Inc. Common Stock
$16.33
1.60 (10.86%)
▲
5d:
+16.64%
30d:
+29.81%
90d:
+44.13%
WAIT
LOW Confidence
Analysis Updated: Aug 14, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When CLYM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: CLYM is 15.3% above its trading range ($14.16). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: CLYM is 15.3% above its trading range ($14.16). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: CLYM is currently trading at $16.33, which is considered extended relative to its 30-day fair value range of $12.25 to $14.16.
Technical Outlook: Technically, CLYM is in a strong uptrend. Immediate support is located at $11.36, while resistance sits at $17.00. The stock is showing strong short-term momentum, up 10.9% recently.
Market Sentiment: CLYM scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.57 (+38.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CLYM is in a strong uptrend. Immediate support is located at $11.36, while resistance sits at $17.00. The stock is showing strong short-term momentum, up 10.9% recently.
Market Sentiment: CLYM scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.57 (+38.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$12.25 -
$14.16
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+15.3% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+10.9%)
- BULLISH: Trading 38.2% below Wall St target ($22.57)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$12.25 -
$14.16
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$11.36
Resistance Level
$17.00
Current Trend
Strong Uptrend
Technical data as of
Aug 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-15.47
Wall Street Target
$22.57
(+38.2%)
Share & Embed Analysis
Last updated: August 16, 2026 2:29 AM ET
Data refreshes hourly during market hours. Next update: 3:29 AM
Data refreshes hourly during market hours. Next update: 3:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLYM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 56 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 42 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$559 | 32 SELL |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$198 | 29 SELL |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 45 HOLD |
